- |||||||||| Biomarker, Review, Journal: Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. (Pubmed Central) - Mar 23, 2022
For prognostic purposes, determining whether the disease is paraneoplastic is of great importance, as myasthenia gravis can be associated with thymoma and Lambert-Eaton myasthenic syndrome with small-cell lung cancer. However, despite well defined diagnostic parameters to classify patients into subgroups, objective biomarkers for use in the clinic or in clinical trials to predict the course of myasthenia gravis and Lambert-Eaton myasthenic syndrome are needed.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
IMMUNE CHECKPOINT INHIBITOR-INDUCED NEUROMUSCULAR DISORDER ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1961;
In this case, IVIG may have stabilized the progression of respiratory symptoms, but ultimately PLEX provided full symptomatic relief. For ICU clinicians, this case highlights the need for prompt recognition and management of this potentially life-threatening adverse drug reaction.
- |||||||||| AN UNUSUAL CASE OF EYELID PTOSIS ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1747;
Recently, there have been multiple cases of reported botulism in middle aged users of black tar heroin, particular in the SouthWest. It is important to consider botulism in a patient who presents with new onset ptosis or patchy weakness and start the appropriate workup and treatment without delay.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Orencia (abatacept) / BMS, Keytruda (pembrolizumab) / Merck (MSD)
RESPIRATORY FAILURE DUE TO PEMBROLIZUMAB-INDUCED SEVERE DIAPHRAGMATIC MYOSITIS: A CASE REPORT ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1617;
Severe myositis is a rare IR-toxicity of the checkpoint inhibitors that, if left untreated, can be fatal. As checkpoint inhibitors become more widely used, clinicians caring for critically ill cancer patients in the community should be aware of this unusual IR adverse event to allow for a prompt diagnostic workup and early management.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
IMMUNE CHECKPOINT INHIBITOR-INDUCED OVERLAP SYNDROME: A CASE SERIES ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1616;
The incidence of rare and potentially fatal IRAE toxicities is increasing with the growing use and indications of ICI therapy. ICU staff managing cancer patients should be aware of the IRAEs and their management.
- |||||||||| A RARE CASE OF CONCURRENT GRAVE DISEASE AND MYASTHENIA GRAVIS CAUSING RESPIRATORY FATIGUE ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1373;
Neurological manifestations of both diseases can overlap, with patients sharing features such as proximal muscle weakness and bulbar symptoms. Care must be taken when treating a patient with both diseases, as drugs used to treat one disorder (such as beta blockers or steroids) can frequently exacerbate the other.
- |||||||||| Journal: Comitant Ocular Deviation in Myasthenia Gravis. (Pubmed Central) - Mar 19, 2022
Comitant ocular deviation can be an ocular manifestation of MG. Its presence does not necessarily indicate a central etiology in patients with MG neither excluding a MG diagnosis.
- |||||||||| prednisone / Generic mfg.
Journal: Effect of Initial Prednisone Dosing on Ocular Myasthenia Gravis Control. (Pubmed Central) - Mar 19, 2022
The study suggests the higher utility of the AChR binding Abs testing in diagnosing OMG due to its high sensitivity, specificity, and positive predictive value. Based on the results of this small retrospective study, it seems initial treatment for ocular myasthenia gravis with a mean maximum daily prednisone dose of 10 mg is similarly effective compared with mean maximum daily dose of 29 mg for control at 1 month.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Journal: Retrospective Analysis of Safety and Outcomes of Rituximab for Myasthenia Gravis in Patients ≥ 65 Years Old. (Pubmed Central) - Mar 19, 2022
At 12 months following initiation of rituximab for MG, patients ≥ 65 years old experienced similarly high rates of improvement in their myasthenic symptoms as younger patients, without an increased risk of experiencing SAEs. Rituximab should be considered in the treatment paradigm in older patients and in non-refractory MG patients of any age.
- |||||||||| Retrospective data, Review, Journal: Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. (Pubmed Central) - Mar 19, 2022
It also represents the positive effect of immunoglobulin or plasma exchange on reducing SFEMG index and QMGS index and the positive effect of Mycophenolate in reducing MG-ADL index, SFEMG and Anti-AChR antibodies index. In addition, based on a meta-analysis of the random-effect model, the overall prevalence of MG in the world is 12.4 people per 100,000 population, which indicates the urgent need for attention to this disease for prevention and treatment.
- |||||||||| Journal: Profile of the single-use, multiple-pass protein A adsorber column in immunoadsorption. (Pubmed Central) - Mar 18, 2022
The single-use, multiple-pass protein A adsorber column is highly efficient to remove IgG1, IgG2 and IgG4 or specific acetylcholine receptor autoantibodies from the plasma. Coagulation parameters should be monitored, since the column has the capacity to largely reduce vitamin K-dependent factors.
- |||||||||| Journal: Effects of Natural Products on Neuromuscular Junction. (Pubmed Central) - Mar 18, 2022
To date, most research has focused on the effect of herbal remedies on cholinesterase inhibitory and antioxidant activities. This review provides leads for identifying potential new drugs from plant sources for the treatment of NMJ diseases.
- |||||||||| Clinical, Journal: Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application. (Pubmed Central) - Mar 17, 2022
According to KEGG analysis, SGR may play a role in the treatment of MG through phosphatidylinositol-3-kinase-protein kinase B signaling pathway, T-cell receptor, cAMP, tumor necrosis factor (TNF), and interleukin-17 (IL-17) signaling pathway, Th17 cell differentiation, endocrine resistance, hepatitis, and some cancer pathways. This study shows that SGR mainly treat myasthenia gravis through the regulation of TNF, MAPK1, JUN, TP53 and other targets, T-cell receptor, TNF, and IL-17 signaling pathway, Th17 cell differentiation and other pathways, which reflects the characteristics of multicomponent, multitarget, and multichannel of traditional Chinese medicine, and providing a certain pharmacological basis for the follow-up study.
- |||||||||| Journal: Focal and asymmetric triceps brachii weakness: a rare but possible myasthenia gravis presentation. (Pubmed Central) - Mar 17, 2022
This study shows that SGR mainly treat myasthenia gravis through the regulation of TNF, MAPK1, JUN, TP53 and other targets, T-cell receptor, TNF, and IL-17 signaling pathway, Th17 cell differentiation and other pathways, which reflects the characteristics of multicomponent, multitarget, and multichannel of traditional Chinese medicine, and providing a certain pharmacological basis for the follow-up study. No abstract available
- |||||||||| Clinical, Journal: Serum irisin levels in patients with myasthenia gravis. (Pubmed Central) - Mar 16, 2022
Serum irisin levels were elevated in patients with MG, suggesting its possible involvement in MG. And irisin is expected to be a signal to evaluate the activities of daily living of OMG patients, while its effect needs further study.
- |||||||||| Zilbrysq (zilucoplan) / UCB
Enrollment closed: RAISE-XT: Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Mar 16, 2022
P3, N=200, Active, not recruiting,
With the aim to guide neurologists in decision-making processes during such scenarios, the study further reviews available data on ICI reintroduction safety in patients with prior n-irAEs. Enrolling by invitation --> Active, not recruiting
- |||||||||| Clinical, Journal: Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. (Pubmed Central) - Mar 15, 2022
The estimated number of prevalent PNS cases in the United States is 17,099, and predicted DALY for all US PNS cases is 292,393 years. Their apparent increasing rate of detection is attributable to increasing physician awareness and availability of serologic testing.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal: Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options. (Pubmed Central) - Mar 15, 2022
• Based on the review of the available case reports and on the cases we described, we consider glucocorticoids, methotrexate, and rituximab as safe and effective options, while the role of Tumor-necrosis factor inhibitors remains uncertain. • Based on the cases we described, Janus Kinase inhibitors are a novel interesting option for patients with concomitant rheumatoid arthritis and myasthenia gravis.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
Review, Journal: TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE. (Pubmed Central) - Mar 15, 2022
Concerning plasmapheresis and intravenous immunoglobulins, both can be used in COVID-19 while taking into consideration thromboembolic properties of the former and hemodynamic disturbances of the latter. As current data suggest, all known COVID-19 vaccines are safe to use in MG patients.
- |||||||||| Retrospective data, Journal: Association between myasthenia gravis and cognitive disorders: a PRISMA-compliant meta-analysis. (Pubmed Central) - Mar 15, 2022
Patients with MG may have cognitive disorders, including those associated with the domains of language, visuospatial function, information processing, verbal immediate and delayed recall memory, visual immediate recall memory and response fluency. Furthermore, the age of onset and disease severity may be associated with cognitive disorders in patients with MG.
- |||||||||| Clinical, Journal: Child with acute weakness: don't forget the salts. (Pubmed Central) - Mar 12, 2022
QUESTION 3: What is the likely diagnosis?Conversion disorder.Myasthenia gravis.Periodic paralysis.Guillain-Barré syndrome.Botulism. QUESTION 4: What interventions can be considered for long-term treatment of this condition?Answers can be found on page 2.
- |||||||||| Journal: Takotsubo Cardiomyopathy in the setting of a Myasthenic Crisis. (Pubmed Central) - Mar 11, 2022
Given that several cardiac complications are known to be associated with myasthenic crisis, cardiac monitoring is advised. Nine reports describe takotsubo cardiomyopathy occurring concurrently with a myasthenic crisis; however, only one report demonstrates this association in the absence of concomitant comorbidities or significant emotional distress.
|
